Ysios Capital reinforces investment role with Dutch AM-Pharma
The venture capital firm has participated in a €12.2-millions round of funding
Catalan venture capital firm Ysios Capital, which specializes in investing in companies in the life sciences arena, has participated, through their first Ysios Biofund, in the €12.2-millions second round of funding of AM-Pharma.
This round of funding has been led by Gilde Healthcare, with support from Ysios Capital and the participation of other international investors. In 2011, Ysios Capital and Kurma Life Sciences led a €29.2-millions first round of funding. Ysios has now invested €5 millions in the Dutch company between the 2011 operation and the one this year. “This latest round of funding shows that Ysios continues financing companies it holds a share of through their growth process,” explained Joël Jean-Mariel, head of the investment in AM-Pharma and Ysios partner.
Biopharmaceutical firm AM-Pharma will devote the funds obtained mainly to developing a Phase II study on their recombinant alkaline phosphatase (recAP) in patients with kidney failure. The study will include 290 patients and be the largest to date on patients with acute kidney injury.
More information is available in the press release.